Ascites Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Companies by DelveInsight

The market size of Ascites is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Ocelot Bio, PharmaIN, Genfit, NovaShunt AG, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Protgen Ltd, Movetis, Sanofi, BioVie Inc., Versantis AG, Ocelot Bio, Inc, Mallinckrodt.

[Nevada, United States] - DelveInsight's "Ascites Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Ascites, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Ascites Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Findings from the Ascites Market Report:
The Ascites market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In August, 2024: Versantis AG announced that a Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)
In June, 2024: Grifols Therapeutics LLC announced that a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites.
In June, 024: Noorik Biopharmaceuticals AG announced that the goal of this clinical trial is to test whether the administration of low doses of ambrisentan can help patients with Hepatorenal Syndrome and to determine if it is safe.
In May, 2024: Wuhan YZY Biopharma Co., Ltd. announced that their Phase 3 clinical study will Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to Paracentesis alone in Patients with Malignant Ascites Caused by Advanced Epithelial Solid Tumors.
In the 7MM, the total cases of Ascites due to cirrhosis in 2022 were 243,682. As per the estimates by DelveInsight, these cases are expected to increase at a substantial CAGR for the study period of 2020-2034.
In 2022, there were 151,474 number of Ascites due to cirrhosis in the United States. In 2022, the number of cases of ascites from ovarian, stomach, breast, and colorectal cancer in the United States were found to be 8,845 , 3,704 , 12,990 , and 10,632 respectively.
Assessments as per DelveInsight's analysts showed that there were 27,265 cases of Grade I ascites due to cirrhosis in the United States in 2022 which was nearly 22% of all grade ascites cases.
Key Ascites Companies are as follows: Ocelot Bio, PharmaIN, Genfit, NovaShunt AG, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Protgen Ltd, Movetis, Sanofi, BioVie Inc., Versantis AG, Ocelot Bio, Inc, Mallinckrodt.
Key Ascites Therapies are as follow: PHIN-214, OCE-205, VS-01, M701, OrsHSA, Tolvaptan, catumaxomab, M0002, Albumin, satavaptan (SR121463B), Rifaximin, Tolvaptan, Prednisolone, Endostar, Cisplatin, OCE-205, Ambrisentan, Terlipressin.
Launching multiple stage Ascites pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Ascites market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ascites Overview:
Ascites (hydroperitoneum is a rare synonym) is defined as an abnormal amount of intraperitoneal fluid. Ascites is a condition in which fluid collects in spaces within the abdomen. If severe, ascites may be painful. The problem may keep the patient from moving around comfortably. Ascites can set the stage for an infection in the abdomen. Fluid may also move into the chest and surround the lungs. This condition can make eating, drinking, and moving around difficult. It can also make it hard to breathe. Ascites can lead to abdominal infections, which may cause kidney failure and can also cause umbilical or inguinal hernias

Ascites Drugs Uptake and Pipeline Development Activities:
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to be launched during the study period. The report covers market uptake by drugs, patient uptake by therapies, and sales of each drug. Additionally, it provides insights into Ascites Pipeline Development Activities, analyzing therapeutic candidates in various stages and key companies involved.

For more information about Ascites companies working in the treatment market: https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ascites Therapies and Key Companies:
PHIN-214: PharmaIN
OCE-205: Ocelot Bio
VS-01: Genfit
M701: Wuhan YZY Biopharma Co., Ltd.
catumaxomab: Neovii Biotech
M0002, Placebo: Movetis
satavaptan (SR121463B): Sanofi
Terlipressin acetate continuous infusion: BioVie Inc.

Ascites Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Ascites.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Ascites Epidemiology Segmentation:
The Ascites market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Ascites Total Prevalence
Ascites Prevalent Cases by severity
Ascites Gender-specific Prevalence
Ascites Diagnosed Cases of Episodic and Chronic

Ascites Market Drivers:
Increasing Prevalence of Liver Diseases
Advances in Diagnostic Techniques
Growing Geriatric Population
Increased Awareness and Early Diagnosis

Ascites Market Barriers:
High Treatment Costs
Complications and Side Effects
Limited Treatment Options for Refractory Ascites
Lack of Awareness in Developing Regions

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Ascites Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Ascites Companies: Ocelot Bio, PharmaIN, Genfit, NovaShunt AG, Wuhan YZY Biopharma Co., Ltd., Neovii Biotech, Protgen Ltd, Movetis, Sanofi, BioVie Inc., Versantis AG, Ocelot Bio, Inc, Mallinckrodt.
Key Ascites Therapies: PHIN-214, OCE-205, VS-01, M701, OrsHSA, Tolvaptan, catumaxomab, M0002, Albumin, satavaptan (SR121463B), Rifaximin, Tolvaptan, Prednisolone, Endostar, Cisplatin, OCE-205, Ambrisentan, Terlipressin.
Ascites Therapeutic Assessment: Current marketed and emerging therapies
Ascites Market Dynamics: Ascites Market drivers and Ascites barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Ascites Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Ascites market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/ascites-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content:

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Ascites Market Overview at a Glance
5 Key Events
6 Epidemiology and Market Forecast Methodology
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Emerging Therapies
11 Ascites: Seven Major Market Analysis
12 Unmet Needs
13 SWOT Analysis
14 KOL Views
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight

Trending Reports:
• Myelofibrosis Market: https://www.delveinsight.com/report-store/myelofibrosis-mf-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-epilepsy-market
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Postmenopausal Vaginal Atrophy Market: https://www.delveinsight.com/infographics/atrophic-vaginitis-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritis-market
• Stable Angina Market: https://www.delveinsight.com/report-store/stable-angina-market
• Turner Syndrome Market: https://www.delveinsight.com/report-store/turner-syndrome-market
• Urolithiasis Market: https://www.delveinsight.com/report-store/urolithiasis-management-devices-market
• Vestibular Schwannoma Market: https://www.delveinsight.com/report-store/vestibular-schwannoma-market
• Wegener S Granulomatosis/granulomatosis With Polyangiitis Market: https://www.delveinsight.com/report-store/wegeners-granulomatosis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.